Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Merck
Mallinckrodt

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR DOFETILIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Dofetilide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00392106 ↗ High Intensity Focused Ultrasound (HIFU) Ablation System Study Suspended ProRhythm, Inc. Phase 3 2006-04-01 The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic drugs.
NCT00657514 ↗ Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease Withdrawn Colorado Prevention Center Phase 4 2008-05-01 After 6 weeks of maximal Ranolazine therapy, tissue hemoglobin desaturation kinetics will change compared to placebo in patients with chronic angina and peripheral arterial disease.
NCT01873950 ↗ Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects Completed Spaulding Clinical Research LLC Phase 1 2013-05-01 This study seeks to compare 4 known QT prolonging drugs versus placebo to determine their effects on electrophysiological and other clinical parameters. The underlying purpose is to determine if depolarization and repolarization effects caused by drugs with differing ionic channel mechanisms can be distinguished from one another, and to gauge the sensitivity and specificity of novel signal analyses for detection of depolarization and repolarization changes. Secondarily, to evaluate the exposure response relationship and drug induced effects on the heart rate biomarker relationship.
NCT01873950 ↗ Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects Completed Food and Drug Administration (FDA) Phase 1 2013-05-01 This study seeks to compare 4 known QT prolonging drugs versus placebo to determine their effects on electrophysiological and other clinical parameters. The underlying purpose is to determine if depolarization and repolarization effects caused by drugs with differing ionic channel mechanisms can be distinguished from one another, and to gauge the sensitivity and specificity of novel signal analyses for detection of depolarization and repolarization changes. Secondarily, to evaluate the exposure response relationship and drug induced effects on the heart rate biomarker relationship.
NCT02308748 ↗ Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block Completed Spaulding Clinical Research LLC Phase 1 2014-05-01 The primary objective of this research study is to test the hypothesis that late sodium current blocking drugs (mexiletine or lidocaine) can attenuate the effect of hERG potassium channel blocking drugs (dofetilide) on ventricular repolarization (QTc) by shortening early repolarization (J-Tpeakc). The secondary object is to assess the ability of calcium channel block (diltiazem) to reduce the QTc prolongation associated with hERG block (moxifloxacin).
NCT02308748 ↗ Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block Completed Food and Drug Administration (FDA) Phase 1 2014-05-01 The primary objective of this research study is to test the hypothesis that late sodium current blocking drugs (mexiletine or lidocaine) can attenuate the effect of hERG potassium channel blocking drugs (dofetilide) on ventricular repolarization (QTc) by shortening early repolarization (J-Tpeakc). The secondary object is to assess the ability of calcium channel block (diltiazem) to reduce the QTc prolongation associated with hERG block (moxifloxacin).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dofetilide

Condition Name

Condition Name for Dofetilide
Intervention Trials
Atrial Fibrillation 2
Drug-induced QT Prolongation 2
Long QT Syndrome 2
Pharmacodynamics 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dofetilide
Intervention Trials
Long QT Syndrome 4
Atrial Fibrillation 2
Peripheral Vascular Diseases 1
Peripheral Arterial Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dofetilide

Trials by Country

Trials by Country for Dofetilide
Location Trials
United States 21
Czech Republic 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dofetilide
Location Trials
Wisconsin 2
Ohio 2
Massachusetts 2
Colorado 2
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dofetilide

Clinical Trial Phase

Clinical Trial Phase for Dofetilide
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dofetilide
Clinical Trial Phase Trials
Completed 4
Withdrawn 2
Suspended 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dofetilide

Sponsor Name

Sponsor Name for Dofetilide
Sponsor Trials
Spaulding Clinical Research LLC 3
Food and Drug Administration (FDA) 3
Brigham and Women's Hospital 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dofetilide
Sponsor Trials
Other 13
U.S. Fed 4
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Dow
Merck
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.